{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:09:25Z","timestamp":1789697365695,"version":"4.0.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Introduce a novel protocol to prevent clotting and citrate accumulation (CA) from blood product transfusion (BPT) during continuous renal replacement therapy (CRRT) with regional citrate anticoagulation (RCA) in children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We prospectively compared fresh frozen plasma (FFP) and platelet transfusions between the two BPT protocols, direct transfusion protocol (DTP) and partial replacement of citrate transfusion protocol (PRCTP), in terms of the risks of clotting, citric accumulation (CA), and hypocalcemia. For DTP, blood products were directly transfused without any adjustment to the original RCA-CRRT regimen. For PRCTP, the blood products were infused into the CRRT circulation near the sodium citrate infusion point, and the dosage of 4% sodium citrate was reduced depending on the dosage of sodium citrate in the blood products. Basic information and clinical data were recorded for all children. Heart rate, blood pressure, ionized calcium (iCa) and various pressure parameters were recorded before, during and after BPT, as well as coagulation indicators, electrolytes, and blood cell counts before and after BPT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-six children received 44 PRCTPs and 15 children received 20 DTPs. The two groups had similar <jats:italic>in vitro<\/jats:italic> ionized calcium (iCa) concentrations (PRCTP: 0.33\u2009\u00b1\u20090.06 mmol\/L, DTP: 0.31\u2009\u00b1\u20090.04 mmol\/L), total filter lifespan (PRCTP: 49.33\u2009\u00b1\u200918.58, DTP: 50.65\u2009\u00b1\u200913.57 h), and filter lifespan after BPT (PRCTP: 25.31\u2009\u00b1\u200913.87, DTP: 23.39\u2009\u00b1\u200911.34 h). There was no visible filter clotting during BPT in any of the two groups. The two groups had no significant differences in arterial pressure, venous pressure, and transmembrane pressure before, during, or after BPT. Neither treatment led to significant decreases in WBC, RBC, or hemoglobin. The platelet transfusion group and the FFP group each had no significant decrease in platelets, and no significant increases in PT, APTT, and D-dimer. The most clinically significant changes were in the DTP group, in which the ratio of total calcium to ionized calcium (T\/iCa) increased from 2.06\u2009\u00b1\u20090.19 to 2.52\u2009\u00b1\u20090.35, the percentage of patients with T\/iCa above 2.5 increased from 5.0% to 45%, and the level of <jats:italic>in vivo<\/jats:italic> iCa increased from 1.02\u2009\u00b1\u20090.11 to 1.06\u2009\u00b1\u20090.09\u2005mmol\/L (all <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05). Changes in these three indicators were not significant in the PRCTP group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Neither protocol was associated with filter clotting during RCA-CRRT. However, PRCTP was superior to DTP because it did not increase the risk of CA and hypocalcemia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1086420","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T05:41:40Z","timestamp":1686807700000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel blood product transfusion regimen to prevent clotting and citrate accumulation during continuous renal replacement therapy with regional citrate anticoagulation in children"],"prefix":"10.3389","volume":"11","author":[{"given":"Yuelin","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxing","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.5144\/0256-4947.2018.260","article-title":"Outcome of continuous renal replacement therapy in critically ill children: a retrospective cohort study","volume":"38","author":"Al-Ayed","year":"2018","journal-title":"Ann Saudi Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/039139880402700104","article-title":"The prospective pediatric continuous renal replacement therapy (ppCRRT) registry: design, development and data assessed","volume":"27","author":"Goldstein","year":"2004","journal-title":"Int J Artif Organs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"732","DOI":"10.2215\/CJN.03200906","article-title":"Demographic characteristics of pediatric continuous renal replacement therapy: a report of the prospective pediatric continuous renal replacement therapy registry","volume":"2","author":"Symons","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1523-1755.2005.67121.x","article-title":"Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy","volume":"67","author":"Goldstein","year":"2005","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/CCM.0b013e318168c590","article-title":"Epidemiology of acute kidney injury: how big is the problem?","volume":"36","author":"Hoste","year":"2008","journal-title":"Crit Care Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1681\/ASN.2004090740","article-title":"Acute kidney injury, mortality, length of stay, and costs in hospitalized patients","volume":"16","author":"Chertow","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000380903","article-title":"Incidence of adverse events during continuous renal replacement therapy","volume":"39","author":"Akhoundi","year":"2015","journal-title":"Blood Purificat"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00134-005-2739-5","article-title":"Impact of anemia on outcome in critically ill patients with severe acute renal failure","volume":"31","author":"du Cheyron","year":"2005","journal-title":"Intens Care Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3737083","DOI":"10.1155\/2019\/3737083","article-title":"Anemia, blood transfusion, and filter life span in critically ill patients requiring continuous renal replacement therapy for acute kidney injury: a case-control study","volume":"2019","author":"Al-Dorzi","year":"2019","journal-title":"Crit Care Res Pract"},{"key":"B10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/0310057X9602400402","article-title":"Continuous renal replacement therapy in critical ill patients: monitoring circuit function","volume":"24","author":"Holt","year":"1996","journal-title":"Anaesth Intens Care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1007\/s001340000676","article-title":"Transfusion requirements during continuous veno-venous haemofiltration: the importance of filter life","volume":"26","author":"Cutts","year":"2000","journal-title":"Intensive Care Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/1744-9987.12224","article-title":"Factors affecting circuit life during continuous renal replacement therapy in children with liver failure","volume":"19","author":"Goonasekera","year":"2015","journal-title":"Ther Apher Dial"},{"key":"B13","first-page":"55","article-title":"Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial","volume":"53","author":"Ramesh Prasad","year":"2000","journal-title":"Clin Nephrol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/cc11455","article-title":"Contrast\u2014induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (part 2)","volume":"17","author":"Lameire","year":"2013","journal-title":"Crit Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1053\/j.jvca.2004.07.016","article-title":"Dose-response relationship between plasma ionized calcium concentration and thrombelastography","volume":"18","author":"James","year":"2004","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"B16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/sdi.12959","article-title":"Anticoagulation strategies in continuous renal replacement therapy","volume":"34","author":"Legrand","year":"2021","journal-title":"Semin Dial"},{"key":"B17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/nep.13656","article-title":"Regional citrate anticoagulation for continuous renal replacement therapy\u2014a safe and effective low-dose protocol","volume":"25","author":"Poh","year":"2020","journal-title":"Nephrology (Carlton)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1542-4758.2012.00730.x","article-title":"Regional citrate anticoagulation in CVVH: a new protocol combining citrate solution with a phosphate-containing replacement fluid","volume":"17","author":"Morabito","year":"2013","journal-title":"Hemodial Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/PCC.0000000000002305","article-title":"The effect of patient- and treatment-related factors on circuit lifespan during continuous renal replacement therapy in critically ill children","volume":"21","author":"Cortina","year":"2020","journal-title":"Pediatr Crit Care Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/0391398819893382","article-title":"Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill children","volume":"43","author":"S\u0131k","year":"2020","journal-title":"Int J Artif Organs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00467-017-3694-4","article-title":"Citrate versus heparin anticoagulation in continuous renal replacement therapy in small children","volume":"32","author":"Raymakers-Janssen","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00467-016-3544-9","article-title":"Regional citrate anticoagulation for continuous renal replacement therapy in children","volume":"32","author":"Persic","year":"","journal-title":"Pediatr Nephrol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00467-013-2690-6","article-title":"Citrate anticoagulation for continuous renal replacement therapy in small children","volume":"29","author":"Jolanta","year":"","journal-title":"Pediatr Nephrol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13054-017-1880-1","article-title":"Complications of regional citrate anticoagulation: accumulation or overload?","volume":"21","author":"Schneider","year":"2017","journal-title":"Critical Care"},{"key":"B25","doi-asserted-by":"publisher","first-page":"R162","DOI":"10.1186\/cc11485","article-title":"Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study","volume":"16","author":"Schultheiss","year":"2012","journal-title":"Crit Care"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1086420\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T05:41:44Z","timestamp":1686807704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1086420\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":25,"alternative-id":["10.3389\/fped.2023.1086420"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1086420","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"article-number":"1086420"}}